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Two-stage estimation to adjust for treatment
switching in randomised trials: a simulation
study investigating the use of inverse
probability weighting instead of
re-censoring
N. R. Latimer1*, K. R. Abrams2 and U. Siebert3,4,5
Abstract
Background: Treatment switching is common in randomised trials of oncology treatments, with control group
patients switching onto the experimental treatment during follow-up. This distorts an intention-to-treat comparison
of the treatments under investigation. Two-stage estimation (TSE) can be used to estimate counterfactual survival
times for patients who switch treatments – that is, survival times that would have been observed in the absence of
switching. However, when switchers do not die during the study, counterfactual censoring times are estimated,
inducing informative censoring. Re-censoring is usually applied alongside TSE to resolve this problem, but results in
lost longer-term information – a major concern if the objective is to estimate long-term treatment effects, as is usually
the case in health technology assessment. Inverse probability of censoring weights (IPCW) represents an alternative
technique for addressing informative censoring but has not before been combined with TSE. We aim to determine
whether combining TSE with IPCW (TSEipcw) represents a valid alternative to re-censoring.
Methods: We conducted a simulation study to compare TSEipcw to TSE with and without re-censoring. We simulated
48 scenarios where control group patients could switch onto the experimental treatment, with switching affected by
prognosis. We investigated various switching proportions, treatment effects, survival function shapes, disease severities
and switcher prognoses. We assessed the alternative TSE applications according to their estimation of control
group restricted mean survival (RMST) that would have been observed in the absence of switching up to the
end of trial follow-up.
Results: TSEipcw performed well when its weights had a low coefficient of variation, but performed poorly
when the coefficient of variation was high. Re-censored analyses usually under-estimated control group RMST,
whereas non-re-censored analyses usually produced over-estimates, with bias more serious when the treatment effect
was high. In scenarios where TSEipcw performed well, it produced low bias that was often between the two extremes
associated with the re-censoring and non-recensoring options.
Conclusions: Treatment switching adjustment analyses using TSE should be conducted with re-censoring, without re-
censoring, and with IPCW to explore the sensitivity in results to these application options. This should allow analysts
and decision-makers to better interpret the results of adjustment analyses.
Keywords: Treatment switching, Treatment crossover, Survival analysis, Overall survival, Oncology, Health technology
assessment, Time-to-event outcomes, Prediction, Re-censoring, Inverse probability weighting
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Background
Treatment switching in randomised controlled trials
(RCTs) has been shown to be an important issue in
health technology assessment (HTA) [1–5]. In oncology
trials patients randomised to the control group are often
permitted to switch onto the experimental treatment
during trial follow-up. This is problematic because it
prevents a standard intention-to-treat (ITT) analysis
from providing the distinct comparison of randomised
treatments that is usually required in HTA. To address
this issue, several HTA agencies around the world have
embraced statistical adjustment methods [5–8]. These
methods allow counterfactual survival times and treat-
ment effects – those that would have been observed
had switching not occurred – to be estimated. However,
concerns around the use of these methods remain –
some agencies are not ready to use adjustment analyses
and those that are may still reject an adjustment ana-
lysis if it is deemed to be inappropriate [5, 9, 10]. Con-
cerns surround the – often untestable – assumptions
made by adjustment methods, but another problem is that
each adjustment method can be applied in a multitude of
ways [9, 10]. Different applications of the same over-arch-
ing method can lead to important differences in results
and decision-makers may therefore be concerned about
the reliability of analyses presented to them – and, pos-
sibly, whether application choices have been made to pro-
duce results most favourable to the new treatment. This
problem is inhibiting the usefulness of adjustment
methods in health care decision making.
Two-stage estimation (TSE) represents a method for
adjusting for treatment switching that has been used
in HTA [1, 11, 12]. The method involves estimating
counterfactual survival times for patients who switch
treatments. Several application choices must be made
– such as which accelerated failure time model to
use, which covariates to include in that model, and
whether or not to include re -censoring. It has been
shown that re -censoring – which will be described
in the next section – can have a substantial impact
on the results of adjustment analyses. Latimer et al.
presented a series of adjustment analyses applied to a
trial analysing the effect of trametinib compared to
chemotherapy in patients with metastatic melanoma,
in which 67% of control group patients switched onto
the experimental treatment [13]. A standard ITT ana-
lysis resulted in a hazard ratio (HR) of 0.72 (95% con-
fidence interval (CI) 0.52 to 0.98), whilst a TSE
analysis yielded a HR of 0.43 (95% CI 0.20 to 0.96)
when re-censoring was applied, and an HR of 0.53
(95% CI 0.29 to 0.97) without re-censoring – see Fig. 1 for
an illustration of the differences between these analyses.
Estimates of overall survival often heavily influence esti-
mates of cost-effectiveness and therefore such substantial
differences in the point -estimate of the overall survival
treatment effect can be crucial in HTA [6, 14–17].
A recently published study investigated the use of
re-censoring and concluded that adjustment analyses
should be conducted with and without re-censoring [18].
Historically it has been recommended that re-censoring
should be applied in adjustment analyses to avoid prob-
lems associated with informative censoring in the counter-
factual dataset [19–21]. However, re-censoring results in a
loss of longer-term information which is problematic
when the objective is to estimate long-term survival times
and treatment effects – which is almost exclusively the
case in HTA [1, 6, 15–17, 21–25]. Latimer et al. found that
across a wide range of scenarios analyses that excluded
re-censoring consistently produced under-estimates of the
longer-term treatment effect, whilst re-censored analyses
produced over-estimates of the treatment effect when the
survivor function was complex, with decreasing hazards
in the longer -term [18]. Whilst this is useful informa-
tion, it is relevant to question whether alternatives to
re -censoring exist, since both re-censoring and non-
recensoring options are prone to bias. Inverse prob-
ability of censoring weights (IPCW) represents a
well-known technique for dealing with informative
censoring [26, 27], and has been suggested as an al-
ternative to re-censoring [21], but to our knowledge
has never been used specifically for this purpose.
In this paper we investigate the use of IPCW com-
bined with TSE instead of re-censoring, to estimate
counterfactual survival times in the presence of treat-
ment switching in an RCT context. We focus on the
problem typically seen in HTA [1–5, 7, 9, 10], whereby a
subset of control group patients switch onto the experi-
mental treatment after disease progression and we wish
to estimate what survival would have been in the control
group as a whole had this switching not occurred. Other
types of switching occur – switching is sometimes trig-
gered by an interim analysis [28] or patients may switch
on to treatments other than those under investigation in
the RCT [1, 5]. The type of switching may influence
whether adjustment is appropriate, and what the target
of estimation should be [29] but these issues are not the
focus of this study. We use the simulation study previ-
ously reported by Latimer et al. [18] but extend it to in-
clude the TSE method in combination with IPCW in
addition to the previously investigated TSE with and
without re-censoring methods. We aim to establish
whether combining TSE with IPCW represents a valid
alternative to re-censoring or not re-censoring.
Methods
The study design has previously been reported by Latimer
et al. [18] In this section we first describe the TSE
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statistical adjustment method and the alternative cen-
soring options, and then summarise the simulation
study design.
Statistical adjustment methods and censoring options
Two-stage estimation (TSE)
The TSE adjustment method is designed to adjust for
switching that occurs after a specific disease-related
time-point (such as disease progression), which is referred
to as a “secondary baseline” [11, 12]. Stage one of the TSE
method involves estimating the effect of switching on
post-secondary baseline survival. Stage two involves using
this estimated effect to derive counterfactual survival
times for switchers. The method is reliant upon the as-
sumption of no unmeasured confounding – information
on prognostic covariates (i.e. independent risk factors for
survival which are associated with switching) is required
at the secondary baseline time-point [11, 12]. In addition,
if switching occurs some time after the secondary baseline,
it must be assumed that no time-dependent confounding
occurs between the secondary baseline time-point and the
time of switch because the TSE only controls for differ-
ences between switchers and non-switchers at the second-
ary baseline time-point [11, 12].
For stage one, post-secondary baseline survival times
in control group patients who switch onto the experi-
mental treatment are compared to those in control
group patients who do not switch. A parametric acceler-
ated failure time model (e.g. Weibull or Generalised
Gamma) is used, controlling for prognostic covariates
measured at the secondary baseline time-point and in-
cluding the switch indicator as a time-dependent vari-
able which equals ‘1’ after the time of switch. This
provides an estimate of the treatment effect associated
with switching (referred to as e−ψ) in the form of a
a
b
Fig. 1 Overall survival in primary efficacy population. a Two-stage method with re-censoring; b Two-stage method without re-censoring.
Adapted from Latimer et al, 2016 [13]
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time-ratio, where e−ψ represents a multiplicative factor
by which an individual’s expected survival time is in-
creased (or decreased) by treatment.
In stage two, the treatment effect estimated in stage
one is used in the following counterfactual survival
model to estimate counterfactual survival times (Ui).
U i ¼ TAi þ e
ψTBi ð1Þ
The counterfactual survival model splits the observed
event time,Ti, for each patient into time spent on the con-
trol treatment, TAi , and time spent on the intervention
treatment, TBi . For control group switchers, TAi is equal
to the time from randomisation until switching occurs,
and TBi is equal to the time from switch until death or
censoring. To estimate counterfactual survival times for
switchers the inverse of the treatment effect estimated in
stage 1 (i.e. eψ) is applied to TBi . If switching was esti-
mated to extend survival in stage one, due to effective
treatment, this will result in counterfactual survival times
being shorter than observed survival times, and vice-versa
if switching was estimated to reduce survival in stage one.
Re-censoring
Informative censoring is a problem for methods such as
TSE that estimate counterfactual survival (and censoring)
times [18–21], which is why it is recommended that
re-censoring is combined with such methods. For TSE the
problem arises because the counterfactual survival model
involves adjusting survival times for switchers but not for
non-switchers. For some switchers the event time (usually
death) may not be observed – instead survival time is cen-
sored. For these patients, the TSE involves adjusting cen-
soring times. Thus, the TSE method involves adjusting
censoring times in switchers, but not in non-switchers.
This will result in informative censoring if there is an as-
sociation between switching and prognosis.
Re-censoring breaks the dependence between the
counterfactual censoring time and switching. Counter-
factual survival times associated with a given value of
ψ (that is, Ui(ψ)) are re-censored for all patients in
the control group at the minimum of the administra-
tive censoring time Ci and Ci exp ψ, representing the
earliest possible censoring time over all possible treat-
ment trajectories, Di ðψÞ. Ui(ψ) is then replaced by D

i
ðψÞ if Di ðψÞ < U iðψÞ.
Alternatives to re-censoring
Evidently, re-censoring results in a loss of longer term sur-
vival information – observed events may be re-censored,
and follow-up time is lost. This is problematic if the ob-
jective is to estimate long-term survival and long-term
treatment effects. If the treatment effect changes over time,
using re-censored survival data would result in inaccurate
estimates of the long-term treatment effect. Similarly, if the
objective was to fit parametric survival models to trial data
in order to extrapolate into the future (as is often the case
in HTA), re-censoring could lead to problems if important
changes to the hazard occur beyond the timeframe of the
re-censored dataset. Such phenomena are unlikely to be
rare – it has often been recognised that cancer populations
are characterised by complex hazard functions [30–32].
Fundamentally, whilst re-censoring avoids the problem of
informative censoring and produces valid estimates of the
treatment effect for the timeframe of the re-censored data-
set, it is problematic when the goal is to estimate the
long-term survival effect associated with a new treatment.
One alternative to re-censoring is to simply not
re-censor. Stages one and two of the TSE method would
be applied to obtain counterfactual survival (and censor-
ing) times for switchers and then the analysis would be
complete, without the extra step of re-censoring. We
denote this method TSEnr. TSEnr is prone to inform-
ative censoring in the counterfactual dataset. A second
alternative is to use IPCW to address the potentially in-
formative censoring in the counterfactual dataset.
TSE combined with inverse probability of censoring weights
(TSEipcw)
Combining TSE with IPCW might be beneficial because
the loss of information associated with re-censoring is
avoided, and the informative censoring associated with
not re-censoring is addressed. We denote this TSE and
IPCW combination as TSEipcw. Stages one and two of
TSE are used to produce a counterfactual dataset for the
control group, and then IPCW is applied to adjust for
informative censoring. The assumptions associated with
TSE are required (switching only after a specified
secondary baseline, and no unmeasured confounding).
The IPCW part of the approach requires correctly speci-
fied weighting models [33], no covariates which ensure
(that is, the probability equals 1) that censoring will
occur [27, 34, 35], and the ‘no unmeasured confounding’
assumption [34, 36]. After TSE has been used to produce
a counterfactual dataset, a model predicting censoring is
fit to the group(s) in which switching occurred in order to
estimate weights, with all censoring events classified as
potentially informative (that is, censoring in switchers and
non-switchers). IPCW is commonly applied working in
discrete time and using pooled logistic regression, mean-
ing that follow-up time is divided up into intervals [27].
The most appropriate time interval duration may depend
upon the data being analysed, but could be monthly,
weekly, or even daily, and the importance of the chosen
duration can be assessed through sensitivity analysis. Sta-
bilised or unstabilised inverse probability of censoring
weights can be estimated. Stabilised weights estimated for
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each individual for each time interval (t), as specified by
Hernan et al. (2001) are [27]:
Wb tð Þ ¼Yt
k¼0
Pr C kð Þ ¼ 0jC k−1ð Þ ¼ 0;A k−1ð Þ;V ;T > k
 
Pr C kð Þ ¼ 0jC k−1ð Þ ¼ 0;A k−1ð Þ; L kð Þ;T > k
 
ð2Þ
where C(k) is an indicator function demonstrating whether
or not censoring had occurred at the end of interval k, and
Cðk−1Þ denotes censoring history to the end of the previous
interval. Aðk−1Þ denotes an individual’s treatment history
up to the end of the previous interval, and V is an array of
an individual’s baseline covariates. LðkÞ denotes the history
of an individual’s time-dependent covariates measured at or
prior to the beginning of interval k and includes V. LðkÞ
should include baseline and time-dependent covariates that
are thought to be prognostic factors for mortality that are
also related to switching (and therefore are predictive of cen-
soring time). The numerator of (2) represents the probability
of an individual remaining uncensored at the end of interval
k given that he or she was uncensored at the end of the pre-
vious interval (k− 1), conditional on baseline characteristics
and treatment history. The denominator of (2) represents
that same probability, but differs from the numerator be-
cause it is conditional on baseline characteristics, treatment
history, and time-dependent characteristics. For unstabilised
weights, the numerator of (2) is simply replaced with ‘1’.
Once inverse probability of censoring weights have
been estimated, they can be used in a weighted survival
analysis, accounting for the potentially informative cen-
soring in the counterfactual dataset.
It is relevant to note that in the context being
discussed here, treatment history drops out of the
weighting model. This may seem strange, given that the
rationale for re-censoring is that treatment history pre-
dicts counterfactual censoring and survival times – it
may be expected that treatment history would be an im-
portant covariate in the censoring model. However, we
are applying IPCW to a counterfactual dataset in which
survival times have been adjusted for treatment switch-
ing – survival and censoring times have been estimated
as if switching had never occurred. Recall that the cen-
soring model is only fit to the group(s) in which switch-
ing occurred – in the context where switching is only
from the control group onto the experimental treatment
the censoring model is only fit to counterfactual control
group data, in which all patients are untreated, leaving
no role for treatment history in the model. For the
TSEipcw combination to work we need to assume that
by including time-updated covariates for factors other
than treatment history we can eliminate any informative
censoring bias present in the counterfactual dataset.
It is also important to note that IPCW has been
used within marginal structural models (MSM) as a
standalone approach to adjust for treatment switch-
ing, with varying degrees of success, and with the
TSE method often producing lower bias than MSM
with IPCW [1, 11, 12]. Here we seek to combine TSE
and IPCW in order to improve performance in the
context of estimating long-term survival.
Simulation study design
In this study we used the same simulation study design
as in our previous study [18], but extended it to investi-
gate whether the TSEipcw method results in an im-
provement in performance compared to TSE with and
without re-censoring. We simulated a subset of the sce-
narios described in Latimer et al. [18] Datasets with a
sample size of 500 were simulated, with 2:1 randomisa-
tion in favour of the experimental group, and with treat-
ment switching from the control group onto the
experimental treatment permitted. True survival times
(without switching) were known. We applied the TSE
adjustment methods with and without re-censoring, and
TSEipcw, and compared the percentage bias in their
estimation of restricted mean survival time (RMST) in
the control group, where RMST was the mean survival
time restricted to the maximum administrative censor-
ing time in the simulated datasets. We focussed on con-
trol group RMST because the objective of the analysis
was to estimate survival times for the control group that
would have been observed in the absence of treatment
switching. We calculated the empirical standard error,
root mean squared error and coverage associated with
estimates of control group RMST. These measures are de-
fined in the “Performance measures” section below. The
simulation study was conducted using Stata software,
version 13.1 [37]. The code used for the simulation study
is provided in Additional file 1: Appendices A and B.
Underlying survival times
A joint survival and longitudinal model was used to sim-
ultaneously generate a continuous time-dependent co-
variate (referred to as ‘biomarker’) and survival times
[38]. Within the data-generating joint model, the longi-
tudinal model for the underlying biomarker value for
the ith patient at time t was:
biomarkeri tð Þ ¼ β0i þ β1t þ β2t  trti þ β3badprog i
ð3Þ
where,
β0i  N β0; σ
2
0
 
:
Here β0i is the random intercept, β1 is the average rate
of change of the biomarker for a patient in the control
group, and β1 + β2 is the average rate of change of the
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biomarker for a patient in the experimental treatment
group. trti is a binary covariate that equals 1 when the
patient is in the experimental group and 0 otherwise,
badprogi is a binary covariate that equals 1 when a pa-
tient has poor prognosis at baseline and 0 otherwise, and
β3 is the change in the intercept for a patient with a
poor prognosis compared to a patient with a good prog-
nosis. Biomarker observations were subject to an error
term with a standard normal distribution with mean 0
and variance σ, and were simulated to occur at random-
isation, and at 21 day intervals thereafter.
We used Crowther and Lambert’s [38] general survival
simulation framework to simulate survival dependent on a
time-varying biomarker, with a 2-component mixture
Weibull baseline survival function, allowing us to simulate
complex hazard functions. The model can be written as:
S0 tð Þ ¼ p exp −λ1t
γ1ð Þ þ 1−pð Þ exp −λ2t
γ2ð Þ ð4Þ
where λ1, λ2 > 0 and γ1, γ2 > 0 are scale and shape pa-
rameters, respectively. The contribution of the first Wei-
bull to the survival model is represented by p, with 0 ≤
p ≤ 1, and 1 − p represents the contribution of the sec-
ond Weibull. The related baseline hazard function is:
h0 tð Þ ¼
λ1γ1pt
γ1−1 exp −λ1t
γ1ð Þ þ λ2γ2 1−pð Þt
γ2−1 exp −λ2t
γ2ð Þ
p exp −λ1tγ1ð Þ þ 1−pð Þ exp −λ2tγ2ð Þ
ð5Þ
The linear predictor of the survival model was incor-
porated as follows:
hi tð Þ ¼ h0 tð Þ
exp δ1 trti þ η t trti þ δ2 badprog i þ α biomarkeri tð Þ
 
ð6Þ
with δ1 representing the direct effect of treatment at
time 0, η representing the rate at which the direct effect
of treatment changes with time, δ2 representing the im-
pact of poor prognosis, and α representing the coeffi-
cient of the underlying biomarker level.
Disease progression times were simulated to equal sur-
vival times multiplied by a value from a beta distribution
with shape parameters (5,10). Disease progression was
assumed to be observed at the first simulated consult-
ation following the progression event, with consultations
occurring every 21 days.
Random entry into the study was simulated, with the
maximum administrative censoring time set at 548 days
(1.5 years). Patients in the control group had a random
uniform entry time from 0 to 183 days and therefore ad-
ministrative censoring times ranged from 365 to 548 days.
In our previous study [18], the complexity of the sur-
vivor function was an important driver of bias associ-
ated with the adjustment methods and therefore we
retained a set of scenarios in which the ‘t’ terms were
excluded from the data generating mechanism, with the
resulting survival model being a single – rather than a
mixture – Weibull model with a constant treatment ef-
fect. The α and η were set to zero. In these scenarios
re-censoring is prone to less bias, because long-term
trends in the hazard are established in the short-term
and the treatment effect is constant.
In line with our previous study [18], scenarios were
ordered such that low numbers were associated with
parameter values that were unlikely to result in major
biases for the adjustment methods, and high numbers
assessed scenarios where bias was more likely to be a
problem. For instance, Scenario 1 had a simple, single
Weibull survival model, a low treatment effect and a
low switching proportion. Scenario 20 provides a more
representative illustration of the scenarios tested, char-
acterised by a mixture Weibull survival model and a
high, time-dependent treatment effect. Parameter
values for the mixture Weibull survival model and the
longitudinal biomarker model in Scenario 20 were:
β0 ¼ 20; σ
2
0 ¼ 1; β1 = 0.04 , β2 = − 0.02, β3 = 2.5, σ = 1,
δ1 = − 1.30, δ2 = 0.3, α = 0.01, λ1 = 0.00001, γ1 = 2.0, λ2 =
0.00001, γ2 = 0.8, p = 0.5, η = 0.003.
Figure 2 presents an example of the Kaplan-Meier
curves and hazard function produced by the simulation
model (in the absence of treatment switching) from a
single simulated data set in Scenario 20. By using a mix-
ture model, we were able to simulate a hazard function
that was initially low, then steadily increased before
decreasing towards the end of the trial follow-up. As has
been previously described, we believe this is reflective of
the types of hazards often observed in a metastatic on-
cology RCT setting [11, 18].
Treatment effect in the experimental group
For the majority of scenarios, the treatment effect simu-
lated in the experimental group cannot be summarised
using a single hazard ratio or acceleration factor, because
our hazard function includes ‘t’ terms. In reality, we
believe that it is likely that the treatment effect (in terms
of a hazard ratio) falls over time, as people discontinue
treatment, or when only better prognosis patients re-
main alive. Therefore, primarily we simulated a treat-
ment effect that initially increased during the period of
greatest hazard, before falling in the longer-term. In the
set of scenarios that excluded the ‘t’ terms from the data
generating model the true treatment effect was known,
with δ1 representing the log hazard ratio. In other sce-
narios, as a summary of the size of the treatment effect
we calculated the ‘average’ HR and acceleration factors
(AF) by generating scenario-specific survival data for a
large number of patients (1,000,000) without applying
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switching, and by fitting Cox and accelerated failure
time models to this.
The switching mechanism
Switching could only occur in control group patients at
one of the three consultations immediately following
disease progression. A logistic function was used to cal-
culate the probability of switching at these consultations,
dependent on the time of observed disease progression
and the observed biomarker value at that time-point.
Switching probabilities were varied to test different
switching proportions, as was the prognosis of patients
most likely to switch. Further details on the probability
of switching in different simulated groups are presented
in Additional file 1: Appendix C.
Treatment effect in switchers
Switchers were simulated to benefit from switching by
multiplying the survival period post switch by a factor
(ω) using the following approach:
T zi ¼ TAi þ ω TBi ð7Þ
where T zi is the survival time incorporating the impact
of switching, TAi represents the time of switching and
TBi represents the survival time after the switch point
that was simulated to occur in the absence of switching.
This is the same as the accelerated failure time model
presented in (1), but here we denote the treatment effect
as ω rather than e−ψ.
In our previous study [18], the magnitude of ω was
varied across scenarios, allowing an assessment of the
impact of the ‘common treatment effect’ assumption,
whereby the effect of the treatment is assumed to be the
same irrespective of when it is received. This was im-
portant because one of the methods tested in our previ-
ous study, the rank preserving structural failure time
model (RPSFTM), assumes that there is a common
treatment effect. In contrast, the TSE method (and
IPCW) has been shown to be unaffected by this assump-
tion [11, 12, 18], and therefore in the present study we
did not vary ω. Instead we set ω equal to the average
Fig. 2 One simulated dataset from Scenario 1 with no switching: (a) Overall survival Kaplan–Meier; (b) Smoothed hazard rate
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acceleration factor observed in the experimental group.
Scenario-specific survival data were generated for
1,000,000 patients without applying switching and an ac-
celerated failure time model was applied to estimate ψ,
with ω then set to equal e−ψ.
Scenarios investigated
Our intention was to investigate realistic scenarios and
to test the sensitivities of the adjustment methods to
changes in key scenario characteristics. Scenarios were
run varying the following characteristics:
 Switch proportion: low (approximately 25% of control
group patients who experienced disease progression);
moderate (approximately 55% of control group patients
who experienced disease progression)
 Treatment effect: low (average HR/AF/ ψ under the
incorrect assumption of proportional treatment effects
approximately 0.80/1.13/− 0.12); high (average HR/AF/
ψ approximately 0.56/1.85/− 0.62)
 Switcher prognosis: good prognosis more likely to
switch; poor prognosis more likely to switch;
 Severity of disease: low (restricted mean survival in
control group approximately 357 days, administrative
censoring proportion approximately 40–50%); high
(restricted mean survival in control group
approximately 228 days, administrative censoring
proportion approximately 17–25%)
 Complexity of the survivor function and time
dependency of treatment effect: simple (single
Weibull model, α = 0.00, η = 0.000); moderate
(mixture Weibull model, α = 0.01, η = 0.003); high
(mixture Weibull model, α = 0.01, η = 0.006)
Using a 2x2x2x2x3 factorial design resulted in a total
of 48 scenarios. The scenarios were numbered 1–48 with
all levels of one factor nested inside one level of the next
factor, following the order listed above. This represents
half of the scenarios reported in Latimer et al. [18]
because in this study we did not include scenarios to test
the sensitivity of the results to the common treatment ef-
fect assumption, because none of the included methods
rely upon this assumption. It is important to note that sce-
narios are ordered differently in the present study, to aid
the presentation of results. For instance, Scenarios 1, 2, 3
and 4 in this study are equivalent to Scenarios 3, 51, 7 and
55 in Latimer et al. [18] One thousand simulations were
run for each scenario. Further details on scenario values
and settings are presented in Additional file 1: Appendices
D and E.
Adjustment methods compared
We applied TSE using a Weibull model with disease
progression as the secondary baseline time-point, and
included covariates for switching, baseline prognosis
group, observed biomarker value at time 0, observed
time-to-disease progression, and observed biomarker
value at disease progression. We included the two-stage
method with and without re-censoring (denoted as TSE
and TSEnr respectively). For TSEipcw, we applied TSEnr
to estimate counterfactual survival and censoring times
for switchers, and then estimated weights according to
eq. (2) using a similar approach to that described by
Fewell et al. [39] Covariates included in V were baseline
prognosis group and the biomarker value observed at time
0. Additional covariates included in LðkÞ were an indicator
for disease progression, observed time-to-disease progres-
sion, and observed biomarker value at the beginning of
the interval. 21-day intervals were used, representing the
observation times simulated in our data, and time was in-
corporated using restricted cubic splines using the Stata
command rcsgen. Interior knots were placed at the 33rd
and 67th centiles of the distribution of censoring times
and 2 boundary knots were placed at the minimum and
maximum values of the censoring times.
For IPCW applications that use stabilised weights, base-
line covariates should be incorporated in survival models
fitted to the weighted survival times. This is computation-
ally intensive in a simulation setting when estimating
mean survival times. Therefore, in the majority of scenar-
ios we applied TSEipcw using only unstabilised weights.
However, in Scenarios 17–20 and 25–28 we applied
TSEipcw with stabilised and unstabilised weights. This
allowed us to investigate the impact of stabilised com-
pared to unstabilised weights in scenarios deemed realistic
(that is, with a moderately complex survivor function).
To provide context on the performance of the various
TSE applications, we included a ‘No Switching’ analysis,
representing the results of a standard ITT analysis (that
is, an unadjusted estimate of control group RMST)
undertaken on the simulated dataset before switching
was applied. This does not represent a feasible estimator,
but provides a useful upper bound for adjustment
method performance which may be considered a ‘gold
standard’. We also included a standard ITT analysis after
switching has been applied.
Performance measures
Control group restricted mean survival time (RMST)
was our estimand upon which we based our perform-
ance measures. This is in line with our aim of investi-
gating the performance of adjustment methods in
estimating counterfactual survival times in the pres-
ence of switching from the control group onto the
experimental treatment. As previously described by
Latimer et al. [18] our simulated survival function
was not analytically tractable so for each scenario we
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simulated data for 1,000,000 patients without incorporating
treatment switching, and estimated the RMST at 548 days
(the maximum administrative censoring time in the simu-
lated datasets). This value is the product of a simula-
tion rather than a calculation so is prone to error,
but this is minimal given the large number of pa-
tients simulated. For instance, in Scenario 1 the
standard error of the control group “true” RMST was
0.28 days (0.07% of the estimated RMST).
To estimate RMST at 548 days for each of the adjust-
ment methods we used flexible parametric models [40].
Non-parametric methods could not be used because
when re-censoring is applied longer-term information is
lost and therefore a non-parametric estimate of RMST
would be restricted to too short a time period. Instead,
we used flexible parametric models fitted to the counter-
factual datasets provided by TSE and TSEnr, and fitted
to the weighted survival times provided by TSEipcw.
These were used to obtain the survivor function extrap-
olated to 548 days, ensuring our RMST comparisons
were comparing “like with like”. The Stata command
stpm2 was used to fit the models on the log cumulative
hazard scale, with 3 interior knots placed at the 25th, 50th
and 75th centiles of the distribution of log survival times
and boundary knots placed at the minimum and
maximum of the distribution of uncensored survival times
[40]. If the final observed counterfactual survival time was
less than 548 days, RMST at 548 days was estimated
through extrapolation using stpm2, which involves a linear
extrapolation of log time on the log cumulative hazard
scale, based on the fitted function and extrapolating from
the last knot. This is consistent with UK HTA recommen-
dations for undertaking survival modelling in the presence
of complex hazard functions [41, 42].
To appropriately estimate confidence intervals for
RMST for TSE and other adjustment methods the entire
adjustment process should be bootstrapped, in order to
take into account the uncertainty in underlying survival
times as well as the uncertainty associated with the adjust-
ment. This involves sampling from the dataset being ana-
lysed multiple times, applying the adjustment method and
estimating RMST for each sample. In a simulation study
setting, with 1000 simulated datasets generated for each
scenario, this is extremely computationally intensive. We
completed this procedure only for the four key scenarios
that we focus on in the Results section. For each simula-
tion we took 200 samples, sampled with replacement,
clustered by individual patient, stratified by treatment
group and using the same sample size as the simulated
datasets (i.e. 500). The adjustment method was applied to
each sample and RMST was calculated. Confidence inter-
vals were then estimated using the 2.5th and 97.5th
percentiles of the calculated RMST over the 200 bootstrap
samples for each simulation.
The performance of methods was evaluated according to
the percentage bias in their estimate of control group
RMST at 548 days. Percentage bias was estimated by taking
the difference between the mean estimated RMST and the
true RMST and expressing this as a percentage of true
RMST [43]. The root mean squared error (RMSE) of the
percentage bias was calculated to provide information on
the variability of estimates in combination with percentage
bias. The empirical standard error (SE) of the RMST esti-
mate was also calculated for each method, defined as the
standard deviation in the percentage bias of the RMST esti-
mate for each method over the 1000 simulations run for
each scenario. Coverage was also calculated, defined as the
proportion of simulations where the 95% confidence inter-
val of the RMST contained the true RMST. Convergence
was measured, defined as the proportion of times that each
method resulted in an estimate of control group RMST.
Percentage bias, RMSE, empirical SE and coverage were
calculated based upon simulations in which convergence
occurred. For each method, Monte Carlo (MC) standard
errors were calculated for each performance measure, in
line with Morris et al. [44] For methods that incorporated
IPCW, we recorded the proportion of simulations in each
Scenario that resulted in maximum weights that were
greater than (i) 100 and (ii) 1000. We also recorded the
coefficient of variation of the weights (that is, the standard
deviation of the weights divided by the mean of the
weights) measured across control group patients in each
simulated data set. This allowed us to explore the relation-
ship between variations in the weights and the performance
of the TSEipcw method.
Results
Results for TSE and TSEnr have been previously re-
ported [18] – to summarise, TSEnr produced positive
bias across almost all scenarios, over-estimating control
group RMST and therefore under-estimating the true
treatment effect. TSE always produced lower estimates
of RMST than TSEnr, consistently producing negative
bias and over-estimating the true treatment effect. Nei-
ther method consistently outperformed the other with
respect to bias in RMST estimates, but TSEnr produced
lower RMSE in every scenario, demonstrating greater
precision than TSE. Here, we focus on the relative per-
formance of the TSEipcw method. We present detailed
results from four key scenarios that illustrate the key
findings. We then summarise the extent to which these
reflect the results of the other scenarios simulated.
Finally we report findings comparing TSEipcw with sta-
bilised and unstabilised weights, and TSEipcw results ac-
cording to the coefficient of variation in the weights.
A summary table describing the characteristics of each
scenario is presented in Additional file 1: Appendix F.
Additional file 1: Appendices G, H and I present the
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percentage bias, empirical standard error and RMSE
respectively across all scenarios for each method.
Detailed results from key scenarios
Table 1 presents detailed results from Scenarios 20 and
28. The characteristics of Scenario 20, with regard to
survival times, switch proportion, treatment effect and
censoring proportion are described in Table 1. This sce-
nario incorporated a large treatment effect, a moderate
switch proportion, and relatively low disease severity
(and therefore a high censoring proportion). As ex-
pected, the ITT analysis over-estimated control group
RMST, equivalent to a percentage bias of 7.5%. The TSE
analysis that incorporated re-censoring under-estimated
control group RMST (percentage bias − 2.3%) and
TSEnr over-estimated control group RMST (percentage
bias 3.5%). TSEipcw led to a higher level of percentage
bias than the other adjustment methods (percentage bias
− 5.1%). The mean coefficient of variation of the inverse
probability of censoring weights was 16.9, and the max-
imum weight was greater than 100 in 77.4% of simula-
tions (and greater than 1000 in 43.5% of simulations).
The only substantive difference between Scenario 20
and Scenario 28 was that disease severity was greater in
Scenario 28, leading to the censoring proportion being
approximately halved. The TSE and TSEnr methods were
relatively unaffected by this change (percentage bias − 3.5
and 4.0% respectively), but the percentage bias produced
by TSEipcw reduced substantially (percentage bias 1.1%),
such that it was lower than that produced by TSE and
TSEnr. Whilst TSE and TSEnr under- and over-estimated
control group RMST respectively, TSEipcw produced an
RMST estimate that was between those two extremes. In
Scenario 28 the mean coefficient of variation of the inverse
probability of censoring weights was 5.4, substantially lower
than that observed in Scenario 20. The maximum weight
was greater than 100 in 53.5% of simulations and was
greater than 1000 in 10.6% of simulations.
Table 2 presents detailed results from Scenarios 25 and
26. Scenario 26 was approximately equivalent to Scenario
28, except the treatment effect was lower. Scenario 25 was
approximately equivalent to Scenario 28 except the treat-
ment effect was lower and the switching proportion was
reduced to approximately 25% of at-risk patients. TSEipcw
performed well in both of these scenarios, producing
percentage bias of 1.8% in Scenario 26 and 1.0% in Scenario
25. The mean coefficient of variation of the inverse prob-
ability of censoring weights was 1.5 in Scenario 26 and 0.9
in Scenario 25. The maximum weight was greater than 100
in 4.7% of simulations in Scenario 25, but was never greater
than 1000. In Scenario 26 the maximum weight was greater
than 100 in 21.2% of simulations and greater than 1000 in
0.3%. Although TSEipcw produced low bias in Scenarios 25
and 26, TSE and TSEnr produced similar or lower bias
(percentage bias 0.3% in both scenarios for TSE, and 1.5
and 1.0% for Scenarios 26 and 25 respectively for TSEnr).
The RMSE results presented in Tables 1 and 2 demon-
strate that the levels of variability associated with the
different adjustment methods differed importantly – as
also demonstrated in our previous study [18]. TSEnr pro-
duced least RMSE (aside from the gold standard ‘no
switching’ analysis) in all four scenarios but did not pro-
duce least bias in any of the scenarios. TSEipcw produced
slightly higher levels of RMSE than TSE in the three sce-
narios in which the mean coefficient of variation of the in-
verse probability of censoring weights was relatively low
(Scenarios 25, 26 and 28), but produced substantially
higher RMSE in Scenario 20, in which the mean coeffi-
cient of variation of the weights was high. The RMSE
results reflect the fact that the empirical standard errors of
Table 1 Scenarios 20 and 28 – performance measures for estimation of control arm RMST
Scenario details Method Percent bias Empirical SE of % bias RMSE of % bias Coverage (%) Convergence (%)
Scenario number: 20
True RMST:
Control: 357
Experimental: 430
Mean switch: 57%
True ave. HR: 0.57
True ave. AF: 1.53
Mean censored: 50%
No switching 0.0 3.7 3.7 94.4 100.0
ITT 7.5 3.4 8.3 46.7 100.0
TSE −2.3 6.9 7.3 97.8 100.0
TSEnr 3.5 3.9 5.3 86.1 100.0
TSEipcw −5.1 16.3 17.1 96.0 95.8
min/max MC error 0.1/0.5 0.1/0.4 0.1/0.5 0.5/1.6 –
Scenario number: 28
True RMST:
Control: 228
Experimental: 322
Mean switch: 57%
True ave. HR: 0.56
True ave. AF: 1.85
Mean censored: 26%
No switching −0.1 5.7 5.7 94.7 100.0
ITT 15.1 5.5 16.0 29.1 100.0
TSE −3.5 9.1 9.8 93.0 100.0
TSEnr 4.0 6.5 7.6 91.6 100.0
TSEipcw 1.1 11.3 11.3 97.1 99.9
min/max MC error 0.2/0.4 0.1/0.3 0.1/0.8 0.5/1.4 –
Note: RMST restricted mean survival time, HR hazard ratio, AF acceleration factor, SE standard error, RMSE root mean squared error, MC Monte-Carlo, ITT intention
to treat, TSE two-stage estimation, TSEnr two-stage estimation without re-censoring, TSEipcw two-stage estimation with inverse probability of censoring weights
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the percentage bias differed substantially between
methods. As shown in our previous study [18], TSE
produced empirical standard errors that were substantially
higher than those associated with TSEnr. These were
higher still for TSEipcw in the four scenarios considered
here – with their size again seemingly related to the size
of the mean coefficient of variation of the inverse prob-
ability of censoring weights.
Tables 1 and 2 show that coverage was around 95–96%
for all the adjustment methods in Scenarios 25 and 26, in
which percentage bias was low for all methods. Coverage
changed in Scenarios 20 and 28, in which levels of percent-
age bias were generally slightly higher than in Scenarios 25
and 26. In Scenario 28 coverage for TSE and TSEnr
decreased to 92–93%. In Scenario 20, which differed to Sce-
nario 28 by having a higher censoring proportion, coverage
associated with TSEnr decreased to 86.1%, whilst remaining
over 95% for TSE and TSEipcw, despite percentage biases
of − 2.3% and − 5.1% respectively. This indicates that for
these methods model standard errors must overestimate
the empirical standard error, because coverage is adequate
despite bias. Coverage was markedly better for the adjust-
ment methods than for the ITT analysis. This is in contrast
to results from previous simulation studies where we did
not use bootstrapping to estimate confidence intervals for
the adjustment methods [11, 12, 18]. Convergence was
achieved with all of the adjustment methods, with the pos-
sible exception of the TSEipcw. Whilst the method con-
verged successfully, in doing so it resulted in weights with a
large range in some simulations, particularly in Scenario 20.
Results from other scenarios
The overall patterns in our results are illustrated in
Figs. 3, 4, and 5, which present nested loop plots for
percentage bias, empirical SE and RMSE [45]. More
detailed barplots for each of these performance mea-
sures are presented in Additional file 1: Appendices G,
H and I. The results presented for Scenarios 20, 25, 26
and 28 provide a good basis for reporting the results of
the remaining scenarios – particularly those observed
in scenarios where the complexity of the survivor func-
tion was moderate or high. The characteristics that had
the most impact on the performance of TSEipcw were
the complexity of the survivor function and the severity
of disease. The complexity of the survivor function, the
switching proportion and the size of the treatment
effect were particularly important for TSE and TSEnr.
The prognosis of switchers was not an important driver
of the results.
TSE, TSEnr and TSEipcw all produced low levels of
bias in Scenarios 1–16, in which the survivor function
was simple, with a constant treatment effect over time.
TSE produced least percentage bias in 6 of these scenar-
ios, and TSEnr and TSEipcw produced least bias in 5
apiece. TSEnr consistently produced lower empirical SE
and RMSE than TSEnr and TSEipcw, and TSEipcw
produced lower empirical SE and RMSE than TSE in 9
of the 16 scenarios. The mean coefficient of variation in
the inverse probability of censoring weights ranged
between 0.6 and 2.3 in these scenarios, the proportion of
simulations in which the maximum weight was greater
than 100 ranged between 1.0 and 34.2% and the propor-
tion of simulations in which the maximum weight was
greater than 1000 ranged between 0 and 1.5%.
When the complexity of the survivor function was
moderate or high, with a decreasing treatment effect
over time, the performance of the adjustment methods
varied much more widely. Scenario 20 provides a useful
representation of the scenarios in which disease severity
was low (that is, Scenarios 17–24 and Scenarios 33–40),
Table 2 Scenarios 25 and 26 – performance measures for estimation of control arm RMST
Scenario details Method Percent bias Empirical SE of % bias RMSE of % bias Coverage (%) Convergence (%)
Scenario number: 25
True RMST:
Control: 228
Experimental: 269
Mean switch: 25%
True ave. HR: 0.78
True ave. AF: 1.30
Mean censored: 18%
No switching 0.1 5.8 5.8 94.9 100
ITT 2.7 5.8 6.4 92.9 100
TSE 0.3 6.4 6.4 95.6 100
TSEnr 1.0 5.9 6.0 94.8 100
TSEipcw 1.0 6.6 6.7 95.3 100
min/max MC error 0.2/0.2 0.1/0.1 0.1/0.2 0.7/0.8 –
Scenario number: 26
True RMST:
Control: 228
Experimental: 269
Mean switch: 57%
True ave. HR: 0.78
True ave. AF: 1.30
Mean censored: 18%
No switching 0.0 5.7 5.7 95.6 100
ITT 6.2 5.6 8.4 85.4 100
TSE 0.3 7.1 7.1 95.2 100
TSEnr 1.5 6.4 6.6 95.3 100
TSEipcw 1.8 8.3 8.5 95.2 100
min/max MC error 0.2/0.3 0.1/0.2 0.1/0.3 0.6/1.2 –
Note: RMST restricted mean survival time, HR hazard ratio, AF acceleration factor, SE standard error, RMSE root mean squared error, MC Monte-Carlo; ITT intention
to treat, TSE two-stage estimation, TSEnr two-stage estimation without re-censoring, TSEipcw two-stage estimation with inverse probability of censoring weights
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Fig. 3 Percentage bias across all scenarios. Note: ITT: intention to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-
censoring; TSEipcw: two-stage estimation with inverse probability of censoring weights
Fig. 4 Empirical standard error across all scenarios. Note: ITT: intention to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-
censoring; TSEipcw: two-stage estimation with inverse probability of censoring weights. SE: standard error
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and Scenarios 25, 26 and 28 reflect the findings in
scenarios in which disease severity was high (Scenarios
25–32 and 41–48). Disease severity did not have an
important effect on the performance of the TSE and
TSEnr methods, but had a large impact on the TSEipcw
method. When disease severity was low, resulting in a rela-
tively high degree of censoring (approximately 40–50%),
TSEipcw consistently produced more bias and considerably
higher empirical SE and RMSE than TSE and TSEnr. In
these scenarios, the mean coefficient of variation in the
inverse probability of censoring weights ranged between 4.7
and 16.9, the proportion of simulations in which the
maximum weight was greater than 100 ranged between
37.7 and 77.4%, and the proportion of simulations in which
the maximum weight was greater than 1000 ranged
between 8.1 and 44.1%. In contrast, when disease severity
was high, resulting in relatively low censoring proportions
(approximately 17–25%), TSEipcw often produced similar
or lower levels of bias than TSE and TSEnr. In these
scenarios, TSE produced least bias in 8 scenarios,
TSEnr produced least bias in 2 scenarios and TSEipcw
produced least bias in 6 scenarios. TSEnr continued to
consistently produce the lowest empirical SE and
RMSE. TSEipcw produced lower empirical SE and
RMSE than TSE in approximately half of these scenar-
ios. The mean coefficient of variation in the inverse
probability of censoring weights ranged between 0.7
and 5.5 in these scenarios, whilst the proportion of sim-
ulations in which the maximum weight was greater
than 100 ranged between 1.5 and 53.5%, and the pro-
portion of simulations in which the maximum weight
was greater than 1000 ranged between 0.0 and 11.6%.
Whilst TSEipcw consistently produced low levels of
bias in scenarios in which disease severity was high
(resulting in low coefficients of variation in the inverse
probability of censoring weights, and few simulations
with very high maximum weights), it did not consist-
ently do better than TSE and TSEnr in these scenarios –
often similar levels of bias were produced by each of the
methods. As shown in our previous study [18], TSE and
TSEnr are prone to higher levels of bias when the treat-
ment effect and/or the switching proportion is high.
Generally, TSEipcw produced lower percentage bias than
TSE and TSEnr when there was a moderate or complex
survivor function and a high treatment effect, provided
disease severity was high, as demonstrated by Scenario
28. When the treatment effect was low, TSE consistently
produced least bias, with TSEnr and TSEipcw producing
similar, marginally higher levels of bias – as demon-
strated by Scenarios 25 and 26.
Stabilised vs Unstabilised weights
Percentage bias, empirical standard error and RMSE
results for applications of TSEipcw with and without sta-
bilised weights across Scenarios 17–20 and 25–28 are
presented in Additional file 1: Appendix J. Applications
of TSEipcw that used stabilised weights generally pro-
duced marginally lower percentage bias than those that
Fig. 5 Root mean squared error across all scenarios. Note: ITT: intention to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without
re-censoring; TSEipcw: two-stage estimation with inverse probability of censoring weights. RMSE: root mean squared error
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used unstabilised weights in scenarios with a low disease
severity – that is, in the scenarios where TSEipcw per-
formed poorly with unstabilised weights. However,
whilst RMSE and mean coefficients of variation in the
weights were substantially reduced in these scenarios
(with mean coefficients of variation ranging from 5.6 to
16.8 for applications with unstabilised weights and 1.8 to
12.0 for stabilised weights), percentage bias and RMSE
remained relatively high compared to TSE and TSEnr.
The proportion of simulations with maximum weights
over 100 was reduced in these scenarios when stabilised
weights were used, but remained high (ranging from
44.6 to 77.4% with unstabilised weights and from 15.1 to
60.9% with stabilised weights).
In scenarios with a high disease severity, TSEipcw ana-
lyses that incorporated stabilised weights generally pro-
duced similar levels of percentage bias compared to
applications that incorporated unstabilised weights, and
RMSE were relatively unaffected. Mean coefficients of
variation were reduced (ranging from 0.9 to 5.4 for applica-
tions with unstabilised weights, and from 0.1 to 0.9 for sta-
bilised weights), as was the proportion of simulations with
maximum weights over 100 (ranging from 4.7 to 53.5%
with unstabilised weights and from 0.0 to 7.3% with stabi-
lised weights). This did not translate to appreciably im-
proved performance except in Scenario 28, which was the
scenario in which the greatest mean coefficient of variation
and proportion of simulations with maximum weight
greater than 100 was observed with unstabilised weights
(coefficient of variation: 5.4, compared to 0.9 with stabilised
weights; proportion of simulations with maximum weight
over 100: 53.5%, compared to 7.3% with stabilised weights).
Notably, in Scenarios 25–27 the mean coefficient of
variation of the weights was always less than 1.5 and
the proportion of simulations with maximum weight
greater than 100 was always less than 14.0%, even
with unstabilised weights.
Impact of variation in weights on TSEipcw performance
Across all scenarios we consistently found that TSEipcw
performed relatively well in scenarios where the mean
coefficient of variation in the weights in the group in
which switching was possible (i.e. amongst control group
patients) was low, producing percentage bias similar to
that produced by TSE and TSEnr. Figure 6 illustrates
the relationship between the mean coefficient of vari-
ation in the inverse probability of censoring weights,
percentage bias, and RMSE. When the mean coefficient
of variation was less than 1.5, TSEipcw produced per-
centage bias that was generally positive and ranged be-
tween − 0.6 and 3.0%. As the mean coefficient of
variation increased, there was a general trend towards
more negative bias, with percentage bias ranging be-
tween approximately − 6.0 and 2.0%. However, whilst
TSEipcw more often produced very low percentage bias
when the mean coefficient of variation was less than 1.5,
it still resulted in relatively high percentage bias (up to
3.0%) in some of these scenarios, and only resulted in
percentage bias that was consistently worse when the
mean coefficient of variation was greater than 6.0. There
appears to be a positive correlation between the mean
coefficient of variation in the inverse probability weights
and RMSE. However, again, whilst TSEipcw more often
resulted in very low levels of RMSE when the mean co-
efficient of variation was less than 1.5, it still resulted in
relatively high RMSE in some of these scenarios, and
RMSE only became consistently worse when the mean
coefficient of variation was greater than 6.0.
There also appears to be a relationship between the
size of the maximum weight and the performance of
TSEipcw. In scenarios in which TSEipcw produced rela-
tively high percentage bias and RMSE, the proportion of
simulations that had maximum weights of greater than
100 and 1000 was high. To investigate this further we
re-estimated percentage bias, empirical SE and RMSE
for TSEipcw in all scenarios, only including simulations
where the maximum weight was (i) ≤ 20; (ii) ≤100; (iii)
≤1000. Results are presented in Additional file 1: Appen-
dix K. Often these analyses resulted in excluding large
numbers of simulations and so they must be interpreted
with caution – for instance, in Scenario 20, only 29 of
the 1000 simulations had maximum weights less than
20; 226 had maximum weights less than 100, and; 565
had maximum weights less than 1000. Patterns in per-
centage bias remained similar to the overall results in
each case. The empirical SE and RMSE associated with
TSEipcw decreased when simulations with maximum
weights of greater than 1000 and greater than 100 were
excluded, especially in scenarios in which TSEipcw pre-
viously exhibited very high empirical SEs (such as
Scenarios 20 and 36), but other changes were minimal.
Discussion
Our study demonstrates the value of combining the
two-stage adjustment method with IPCW to correct for
informative censoring in counterfactual datasets derived
when adjusting for treatment switching in clinical trials.
We have demonstrated that the TSEipcw approach gen-
erally performs well when the estimated weights have a
low coefficient of variation. Previous research has dem-
onstrated that adjustment analyses that use re-censoring
to address the informative censoring problem are likely
to produce biased estimates of long-term control group
mean survival time in situations where the survivor
function is complex, with important changes in the haz-
ard function over time [18]. For instance, when hazards
decrease towards the end of trial follow-up (as simulated
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in the majority of scenarios in the present study),
re-censoring is likely to cause this trend to be missed,
resulting in under-estimates of long-term mean survival.
In contrast, analyses that do not apply re-censoring are
likely to produce over-estimates of long-term control
group mean survival time (hence under-estimates of the
treatment effect) [18]. Given this, using IPCW in com-
bination with the TSE adjustment method represents a
valid additional option for an analyst attempting to avoid
the pitfalls of either re-censoring or not re-censoring. In
the right circumstances, the TSEipcw approach can be
used to enhance analyses presented to decision-makers
who are interested in estimating long-term treatment ef-
fects in trials confounded by treatment switching.
The TSEipcw method produced lower percentage bias
than the re-censoring and non-re-censoring options in 11
of the 48 scenarios, and in 9 of these it produced bias that
was intermediate in relation to the negative bias produced
Fig. 6 Impact of mean coefficient of variation in weights on TSEipcw performance: (a) percent bias; (b) Root mean squared error. Note: TSEipcw:
two-stage estimation with inverse probability of censoring weights
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by TSE and the positive bias produced by TSEnr. TSEipcw
was most likely to produce lower bias than TSE and
TSEnr when the treatment effect was high – in these sce-
narios re-censoring results in a large amount of lost infor-
mation, whilst not re-censoring results in more important
informative censoring bias. In several other scenarios
TSEipcw produced percentage bias that was of a similar
size to that produced by TSE and TSEnr. It may be argued
that TSEipcw has theoretical advantages over TSE and
TSEnr, given the HTA context where the objective is to
estimate long-term survival. Re-censoring is sub-optimal
because it leads to a loss of longer-term information,
whilst a failure to re-censor means that results are prone
to informative censoring bias. TSEipcw does not involve a
loss of information and protects against informative cen-
soring bias, provided the no unmeasured confounding as-
sumption is satisfied.
However, we found that TSEipcw has important limita-
tions in several of the scenarios that we simulated.
TSEipcw was the worst performing adjustment method in
scenarios where the mean coefficient of variation of the
weights was high and where a large proportion of simula-
tions had very high weights (greater than 100). Our results
suggest that if the coefficient of variation is less than
approximately 1.5, TSEipcw is likely to perform consist-
ently and well. When the coefficient of variation is higher,
the method becomes more inconsistent and prone to
higher levels of bias and RMSE, and should not be relied
upon. Notably, this coefficient of variation is measured
only across patients in the control group, as these were
the only patients to which weights were applied in our
study. The coefficient of variation would be substantially
reduced if we included experimental group patients in its
estimation, because all these patients received weights of 1
across all time-periods. Our findings are in line with previ-
ous research, which has shown that IPCW methods be-
come prone to substantial error when observations are
assigned extreme weights [11, 12, 33]. In this study, high
weight variation was often observed in scenarios with low
disease severity (and thus a high censoring proportion),
but this was not always the case. In fact, high weight vari-
ation was only observed when disease severity was low
and the simulated disease mechanism was such that a sub-
stantial proportion of patients censored at the end of the
study had not experienced disease progression. Import-
antly, we conclude that TSEipcw will not necessarily
perform poorly in the presence of a high censoring pro-
portion – rather, it becomes prone to bias when the coeffi-
cient of variation in the weights is high, irrespective of the
reason for the large range in the estimated weights.
We also found that the performance of TSEipcw was
relatively poor in scenarios with a high proportion of
simulations that resulted in very high maximum weights.
However, we are unable to conclude what size maximum
weight is “too large” – in scenarios in which TSEipcw
performed poorly it generally continued to perform
poorly even when simulations with maximum weights of
greater than 20 were excluded. In practice, choosing an
optimal weighting model is not straightforward. Previous
research has shown that changing the model specifica-
tion can result in drastically different weights [46]. It
therefore follows that various model specifications
should be explored. Weight truncation could be consid-
ered, though this should be used with caution as it may
re-introduce bias [46].
Given our suggestion that replacing re-censoring
with IPCW represents a valid option, the limitations
of this approach should be considered. In particular,
in this context IPCW is applied to a counterfactual
dataset. IPCW analyses rely upon the ‘no unmeasured
confounding’ assumption, and therefore require infor-
mation on baseline and time-dependent covariates
that are prognostic for survival and predict censoring.
In the context where TSE is used to adjust survival
times to account for treatment switching, and then
IPCW is applied to the resulting counterfactual data-
set, observations on time-varying characteristics (such
as biomarker values) beyond the point of switching
are of questionable use because they may have been
affected by the treatment switch. In our simulations,
we had perfect information on such variables, because
we simulated their values prior to applying treatment
switching – reflecting a situation where time-varying
values beyond the switch point could be perfectly
predicted, adjusted for switching. In reality, structural
mean models may be required to estimate these
values, further complicating the analysis. To test the
sensitivity of the TSEipcw method to violations of the
no unmeasured confounding assumption, we included
a version of the TSEipcw analysis that assumed that
no information was available on the time-varying bio-
marker, and hence the only time-varying information
included in the weighting model was progression time
– which represented time-varying information that
was not affected by treatment switching because
switching only happened after disease progression.
This approach performed almost identically to the ap-
proach that incorporated full information on the
time-varying biomarker, because there was a strong
association between the biomarker and progression
time in our simulated datasets. This may not always be
the case – in practice, clinical expert knowledge and
causal pathways should be examined to identify whether
values of time-dependent variables need to be predicted
beyond the switching time-point in order to adequately
satisfy the no unmeasured confounding assumption.
A further limitation of the IPCW approach in this
context is that random entry into the study combined
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with a calendar-date study end time-point may result in
very low numbers at risk at the end of the study
follow-up period, resulting in large weights for the
remaining observations. We did not attempt to address
this issue in our simulation study, and TSEipcw still per-
formed well in several scenarios. In reality a small
amount of re-censoring could be applied to avoid this
problem if it was identified as the reason for obtaining
large weights. This would involve the loss of some
longer-term information, but substantially less than
under the full re-censoring approach.
Our study has limitations. As previously described, a
simulation study can never be exhaustive in relation to
the scenarios investigated, alternative methods could be
used to generate the simulated datasets, and alternative
endpoints could be considered important for different
contexts [18]. We believe that our simulation mechan-
ism allowed us to generate realistic datasets, and our
endpoint of restricted mean survival is relevant given
our focus on analyses used to inform HTA analyses,
whilst avoiding the problems associated with extrapola-
tion that would have arisen had we have chosen to focus
on even longer term (perhaps lifetime) mean survival.
It may be considered to be a limitation that we would not
expect any of the adjustment methods to work perfectly in
our simulated scenarios, because underlying survival times
were simulated using a mixture Weibull model incorporat-
ing a time-dependent covariate, whereas we used flexible
parametric spline-based models to estimate the RMST as-
sociated with each method adjustment. We included the
correct variables within the adjustment models and there-
fore the no unmeasured confounders assumption held, but
the underlying survival models were different. This was
intentional because in reality true underlying survival
models are unknown. Common practice in HTA is to use a
flexible parametric model if the observed hazards are com-
plex (i.e. with turning points) [41, 42] and therefore we took
this approach in this study.
Perhaps the most important limitation of our study is
that in most scenarios we simulated a complex hazard
function which first increased and then decreased within
the study period. This is a key driver of the results associ-
ated with the application of TSE that applied re-censoring,
because the associated loss of longer-term information
was important – an important change in the trend in the
hazard was missed when longer-term information was
lost, resulting in biased estimates of mean survival time
restricted to the end of the simulated trial follow-up
period. As previously stated, we believe that the haz-
ard and survival functions that we simulated are real-
istic, but in some cases such trends in the hazard
may not be observed; turning points or changes in
slope of the hazard function may occur beyond the
end of the trial, or may not occur at all. In such
cases, re-censoring should not result in bias due to
lost longer-term trial information.
It is also relevant to note that we only incorporated the
two-stage adjustment method in this study – we did not in-
clude the rank preserving structural failure time model
(RPSFTM) [47]. The RPSFTM has the same problems asso-
ciated with censoring as the two-stage method, and there-
fore combining the RPSFTM with IPCW represents an
alternative to re-censoring in the same way that it does for
TSE. We did not assess RPSFTM combined with IPCW be-
cause doing so is not straightforward: inverse probability of
censoring weights would need to be estimated for every
value of ψ included within the g-estimation process. This
would be computationally intensive, especially within a
simulation study where thousands of analyses are con-
ducted. Therefore, we focussed our investigation on the
two-stage method. In theory, we would expect IPCW to
perform similarly when combined with RPSFTM as when
combined with TSE, because in both cases it is simply being
applied to a counterfactual dataset in which adjustments
have been made for treatment switching.
Conclusions
Incorporating IPCW within two-stage adjustment ana-
lyses represents a credible alternative to re-censoring or
not re-censoring, provided that estimated weights are
not extreme in size and have relatively low variation.
The characteristics of the trial and treatment under in-
vestigation and the objectives of the research are import-
ant to consider: if the objective is to estimate long-term
treatment effects and there is likely to be important
changes in the hazard function and the treatment effect
over time, re-censored analyses are prone to bias due to
lost longer-term information, and non-re-censored ana-
lyses are prone to informative censoring bias. These
problems are particularly important when the treatment
effect is high. Provided the no unmeasured confounding
assumption is reasonable and that estimated weights
have low variation, we recommend presenting TSEipcw
alongside adjustment analyses with and without
re-censoring to provide decision-makers with enhanced
information on the range in which the true treatment ef-
fect is likely to lie. If weights have high variation
TSEipcw should not be relied upon, and we recommend
considering the characteristics of the trial and the results
of previous research [18] to help determine whether
re-censoring or not re-censoring represents the ap-
proach likely to result in least bias.
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